This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Marc L. Schwartz, MD

Arch Intern Med. 1993;153(17):2050-2052.

Abstract
Hypocholesterolemic drug therapy has become a major focus of cardiovascular medicine because recent evidence has demonstrated that optimization of serum lipid levels results in decreased atherosclerotic cardiovascular risk. Niacin, a B-complex vitamin, is capable of lowering total serum cholesterol and triglyceride levels while simultaneously raising serum high-density lipoprotein cholesterol levels. However, the use of niacin can be complicated by the development of hepatotoxicity, hyperuricemia, and modest hyperglycemia. A patient is described who had an excellent lipid response to niacin therapy but developed the previously undescribed complication of severe, life-threatening hyperglycemia. Therefore, despite its low cost and demonstrated efficacy, because of potential very toxic side effects, niacin therapy needs to be carefully monitored.

(Arch Intern Med. 1993;153:2050-2052)

Author Affiliations
From the Division of Cardiology, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Achieving the therapeutic benefits of Niaspan(R) in daily practice
Reasner
Eur Heart J Suppl 2006;8:F68-F73.
ABSTRACT | FULL TEXT  

Modern intervention strategies for managing dyslipidaemia: the case for combination therapy
Drexel
British Journal of Diabetes & Vascular Disease 2005;5:S17-S23.
ABSTRACT